Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20
Executive Summary
While not perfect, the latest Phase II data for the stromal depleting agent PEGPH20 give cause for optimism for hyaluronan as a biomarker in pancreatic cancer and for Halozyme's Phase III strategy.